E

Euroapi SAS
PAR:EAPI

Watchlist Manager
Euroapi SAS
PAR:EAPI
Watchlist
Price: 2.694 EUR 3.22% Market Closed
Market Cap: 257.5m EUR

EV/EBITDA
Enterprise Value to EBITDA

3.6
Current
2.4
Median
12.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
3.6
=
Enterprise Value
247.2m EUR
/
EBITDA
68.3m EUR
Market Cap EV/EBITDA
FR
Euroapi SAS
PAR:EAPI
256.5m EUR 3.6
US
Eli Lilly and Co
NYSE:LLY
712.7B USD 34.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
368.9B USD 12.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 13.3
CH
Roche Holding AG
SIX:ROG
211.1B CHF 9.6
UK
AstraZeneca PLC
LSE:AZN
162.1B GBP 130.6
CH
Novartis AG
SIX:NOVN
182.9B CHF 10.1
US
Merck & Co Inc
NYSE:MRK
197.1B USD 8.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
133.1B USD 7.3
EBITDA Growth EV/EBITDA to Growth
FR
E
Euroapi SAS
PAR:EAPI
Average EV/EBITDA: 394.3
3.6
26%
0.1
US
Eli Lilly and Co
NYSE:LLY
34.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
14%
1
CH
Roche Holding AG
SIX:ROG
9.6
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
3.4
2-Years Forward
EV/EBITDA
2.5
3-Years Forward
EV/EBITDA
1.8